SFL
27.4.2020 18:35:11 CEST | Business Wire | Press release
Regulatory News:
SFL (Paris:FLY):
Consolidated revenue by business segment (€000's) |
|||
|
|
Q1 2020 |
Q1 2019 |
Rental income |
46,638 |
48,504 |
|
o/w |
Paris Central Business District |
39,209 |
40,416 |
|
Paris Other |
6,832 |
7,613 |
|
Western Crescent |
598 |
475 |
Other revenue |
0 |
0 |
|
Total consolidated revenue |
46,638 |
48,504 |
|
First-quarter 2020 consolidated rental income amounted to €46.6 million, down by a slight €1.9 million or 3.8% from the €48.5 million reported for the same period in 2019.
- On a like-for-like basis (excluding all changes in the portfolio affecting period-on-period comparisons), rental income rose by €0.9 million (1.9%), primarily as a result of index increases, and the occupancy rate was stable at around 97% in both periods.
- Rental income from spaces being redeveloped was down by €2.1 million, mainly following the renovation of several floors in the 103 Grenelle and Edouard VII buildings that were vacated in late 2019 and early 2020.
- Lastly, no income from penalties was received in first-quarter 2020, unlike in the same period of 2019 when penalties of €0.6 million were received.
The physical occupancy rate for revenue-generating buildings remained high, at 97.0% at 31 March 2020 (versus 97.4% as of 31 December 2019), while the EPRA vacancy rate stayed low, at 1.9%.
No properties were purchased or sold during the first quarter of 2020.
SFL's consolidated net debt was very slightly higher at 31 March 2020, at €1,740 million (compared with €1,732 million at 31 December 2019), representing a loan-to-value (LTV) ratio of 22.8% based on the portfolio’s appraisal value at 31 December 2019.
The Group’s liquidity position at 31 March 2020 was excellent, with €890 million in undrawn confirmed lines of credit and cash at bank and in hand of €116 million.
Covid-19 health crisis
SFL’s greatest strengths in the current situation are its strategic positioning and low LTV.
It is still difficult to assess the direct and indirect effects of the public health crisis on SFL’s business and results, but all possible measures are being taken to limit the impact and their effectiveness is monitored on a daily basis.
The Group acted swiftly to ensure that all of its properties could remain open and available for use by tenants. The only services no longer available are those that would breach current health measures (mainly mass catering services).
Rental income: SFL is largely unaffected by government measures concerning small retail outlets because of its strategic focus on prime office properties in Paris. The handful of requests received from tenants are analysed on a case-by-case basis and the Group endeavours to support them as far as possible during this difficult period, for example by allowing them to defer payment of their rent for the second quarter of 2020.
Redevelopment and renovation projects: these projects have been halted for the time being, and contractors are currently determining the necessary measures for work to resume, with an ever-present focus on safety conditions. Delivery of the projects will most likely be delayed by a few months due to these disruptions, but while it is too early to make any reliable estimate of the impact of these delays, it is expected to be limited.
Property leasing activities: the rental market has slowed without coming to a complete halt; however, SFL is largely unaffected because it has very few vacant units immediately available for rental. The major property leasing challenges concern the 83 Marceau and Biome properties that are currently being redeveloped and will be delivered in 2021/2022.
A citizen-based approach
To ensure business continuity while also protecting employees, all of SFL’s teams are working from home on full pay, with no temporary lay-offs.
Lastly, SFL has contributed to the collective effort to fight the pandemic, by donating €550,000 to the Fondation de France’s programmes in support of hospitals and health workers, medical research and assistance for vulnerable people. The Group has also offered to make one of its vacant properties available to the urban affairs ministry to provide emergency housing.
About SFL
Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.
Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA
S&P rating: BBB+ stable outlook
View source version on businesswire.com: https://www.businesswire.com/news/home/20200427005657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
